Premium
Therapeutic approaches‐ aflibercept first french results of intravitreous aflibercept for active naïve polypoidal choroidal vasculopathy‐6 months follow up
Author(s) -
DIRANI A,
COSCAS F,
COSCAS G,
SEMOUN O,
SOUIED E
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.2414.x
Subject(s) - aflibercept , medicine , ophthalmology , visual acuity , fluorescein angiography , indocyanine green angiography , retinal , surgery , bevacizumab , chemotherapy
To evaluate the anatomical and functional effect of intravitreous aflibercept (IAI) for the treatment of polypoidal choroidal vasculopathy (PCV) associated with exudative AMD, with a follow up of 3 months.This is a case series study that included 22 eyes with active PCV. All eyes were naive to treatment before inclusion in the study. The treatment protocol consisted of an induction phase of 3 IAI, then the injections were done every 2 months. A complete ophthalmologic workup was done for every patient and included: best corrected visual acuity (ETDRS scale), Fluorescein and Indocyanine Green Angiography, EDI‐OCT (Spectralis HRA+OCT®, Heidelberg engineering). All results were analyzed at inclusion and at 3 months.The mean age was 76.3 +/‐ 11.3. Male to female ratio was 1. The BCVA improved at 3 months (0.58 +/‐ 0.39logMAR vs 0.20±0.27 log MAR; p= 0.01). The patients gained a mean of 15 letters in the BCVA. No loss of BCVA was noted in any patient. The central macular thickness improved significantly from 376.77+/‐99.54 to 279.80±82.53 at 3 months (p= 0.043).The polyp’s regression started at one month after the first injection and was almost complete at 3 months. A significant improvement of retinal pigment epithelium detachment